Paul Maddison

List of Publications by Year
in descending order

52 papers	3,056 citations	257101 24 h-index	243296 44 g-index
52 all docs	52 docs citations	52 times ranked	2827 citing authors

#	Article	IF	Citations
1	Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain, 2014, 137, 2178-2192.	3.7	430
2	Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain, 2002, 125, 1887-1895.	3.7	419
3	Clinical Dutch-English Lambert-Eaton Myasthenic Syndrome (LEMS) Tumor Association Prediction Score Accurately Predicts Small-Cell Lung Cancer in the LEMS. Journal of Clinical Oncology, 2011, 29, 902-908.	0.8	210
4	Favourable prognosis in Lambert-Eaton myasthenic syndrome and small-cell lung carcinoma. Lancet, The, 1999, 353, 117-118.	6.3	208
5	Neuromyotonia. Clinical Neurophysiology, 2006, 117, 2118-2127.	0.7	139
6	Myasthenia gravis: Association of British Neurologistsâ€™ management guidelines. Practical Neurology, 2015, 15, 199-206.	0.5	127
7	Intracellular and non-neuronal targets of voltage-gated potassium channel complex antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 353-361.	0.9	124
8	The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2011, 82, 671-673.	0.9	107
9	Distinct HLA associations of LGI1 and CASPR2-antibody diseases. Brain, 2018, 141, 2263-2271.	3.7	100
10	Paraneoplastic neurologic disorders in small cell lung carcinoma. Neurology, 2015, 85, 235-239.	1.5	99
11	Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain, 2017, 140, 1212-1219.	3.7	89
12	Immunobiomarkers in Small Cell Lung Cancer: Potential Early Cancer Signals. Clinical Cancer Research, 2011, 17, 1474-1480.	3.2	87
13	TIA1 variant drives myodegeneration in multisystem proteinopathy with SQSTM1 mutations. Journal of Clinical Investigation, 2018, 128, 1164-1177.	3.9	75
14	Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurology, The, 2022, 21, 176-188.	4.9	74
15	Long-term survival in paraneoplastic Lambert-Eaton myasthenic syndrome. Neurology, 2017, 88, 1334-1339.	1.5	62
16	Which antibody and which cancer in which paraneoplastic syndromes?. Practical Neurology, 2010, 10, 260-270.	0.5	59
17	Clinical electrophysiological characterization of the acquired neuromyotonia phenotype of autoimmune peripheral nerve hyperexcitability. Muscle and Nerve, 2006, 33, 801-808.	1.0	53
18	MT-ND5 Mutation Exhibits Highly Variable Neurological Manifestations at Low Mutant Load. EBioMedicine, 2018, 30, 86-93.	2.7	47

#	Article	IF	Citations
19	Strength-duration properties of peripheral nerve in acquired neuromyotonia. , 1999, 22, 823-830.		45
20	Autoimmunity to SOX2, clinical phenotype and survival in patients with small-cell lung cancer. Lung Cancer, 2010, 70, 335-339.	0.9	43
21	Paraneoplastic neurological autoimmunity and survival in small-cell lung cancer. Journal of Neuroimmunology, 2008, 201-202, 159-162.	1.1	40
22	Treatment for Lambert-Eaton myasthenic syndrome. , 2005, , CD003279.		38
23	Human hippocampal CA3 damage disrupts both recent and remote episodic memories. ELife, 2020, 9, .	2.8	37
24	Circulating microRNA miR-21-5p, miR-150-5p and miR-30e-5p correlate with clinical status in late onset myasthenia gravis. Journal of Neuroimmunology, 2018, 321, 164-170.	1.1	31
25	Treatment in Lambertâ€“Eaton myasthenic syndrome. Annals of the New York Academy of Sciences, 2012, 1275, 78-84.	1.8	29
26	Novel Humoral Prognostic Markers in Small-Cell Lung Carcinoma: A Prospective Study. PLoS ONE, 2015, 10, e0143558.	1.1	28
27	Forecasting stroke-like episodes and outcomes in mitochondrial disease. Brain, 2022, 145, 542-554.	3.7	25
28	A Prospective Study of the Incidence of Myasthenia Gravis in the East Midlands of England. Neuroepidemiology, 2019, 53, 93-99.	1.1	24
29	The UK Myotonic Dystrophy Patient Registry: facilitating and accelerating clinical research. Journal of Neurology, 2017, 264, 979-988.	1.8	23
30	Identification of GAA variants through whole exome sequencing targeted to a cohort of 606 patients with unexplained limb-girdle muscle weakness. Orphanet Journal of Rare Diseases, 2017, 12, 173.	1.2	21
31	The Association of British Neurologists' myasthenia gravis guidelines. Annals of the New York Academy of Sciences, 2018, 1412, 166-169.	1.8	21
32	Ocular presentation of myasthenia gravis: A natural history cohort. Muscle and Nerve, 2018, 57, 622-627.	1.0	19
33	Acquired neuromyotonia in a patient with spinal epidural abscess. , 1998, 21, 672-674.		18
34	Body composition and clinical outcome measures in patients with myotonic dystrophy type 1. Neuromuscular Disorders, 2017, 27, 286-289.	0.3	15
35	False-positive acetylcholine receptor antibody results in patients without myasthenia gravis. Journal of Neuroimmunology, 2019, 332, 69-72.	1.1	14
36	Clinical and Myopathological Characteristics of Desminopathy Caused by a Mutation in Desmin Tail Domain. European Neurology, 2012, 68, 279-286.	0.6	13

#	Article	IF	Citations
37	The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders. Journal of Neuroimmunology, 2019, 326, 14-18.	1.1	12
38	Neurology training in the United Kingdom: a diagnostic analysis of over 5000 patients. Journal of Neurology, 2005, 252, 605-607.	1.8	11
39	Effects of aspirin on small-cell lung cancer mortality and metastatic presentation. Lung Cancer, 2017, 106, 67-69.	0.9	9
40	Lung cancer prediction in Lambert-Eaton myasthenic syndrome in a prospective cohort. Scientific Reports, 2020, 10, 10546.	1.6	8
41	Neuronal antibody detection and improved lung cancer prediction in Lambert-Eaton myasthenic syndrome. Journal of Neuroimmunology, 2020, 340, 577149.	1.1	8
42	Autoantibodies to glutamic acid decarboxylase in patients with epilepsy and their relationship with type 1 diabetes: a pilot study: TableÂ1. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 676-677.	0.9	5
43	Prospective study of cancer survival in patients with HuD-antibody-associated paraneoplastic neurological disorders. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1350-1351.	0.9	4
44	Clinical and Pathological Features of Mitochondrial DNA Deletion Disease Following Antiretroviral Treatment. JAMA Neurology, 2015, 72, 603.	4.5	3
45	Prospective Study of Lambert-Eaton Myasthenic Syndrome in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 1309-1310.	0.5	1
46	Lambertâ€"Eaton myasthenic syndrome and cerebellar ataxia: is Response to immunotherapy a clue to pathogenesis?. Muscle and Nerve, 2018, 58, 4-6.	1.0	1
47	A diagnostic conundrum. Practical Neurology, 2018, 18, 137-142.	0.5	1
48	RETROGRADE AMNESIA FOLLOWING AUTOIMMUNE LIMBIC ENCEPHALITIS. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, e4.79-e4.	0.9	0
49	Autoantibodies in the Lambert-Eaton Myasthenic Syndrome (LEMS) and Amyotrophic Lateral Sclerosis (ALS). , 2014, , 629-636.		0
50	1712â€…â€˜Less contented as a personâ€™: preliminary data from the lgi1-qol study. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A7.1-A7.	0.9	0
51	Lambert-Eaton Myasthenic Syndrome. , 2014, , 1089-1099.		0
52	Splicing in two skeletal muscle transcripts correlates with clinical phenotype in myotonic dystrophy type 1 patients. Journal of Neurology, 2022, , 1.	1.8	0